Moors & Cabot’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.39M | Sell |
12,415
-2,201
| -15% | -$237K | 0.09% | 206 |
|
|
2026
Q2 | $1.02M | Buy |
14,616
+4,700
| +47% | +$243K | 0.04% | 382 |
|
|
2026
Q1 | $504K | Sell |
9,916
-6,556
| -40% | -$306K | 0.02% | 550 |
|
|
2025
Q4 | $486K | Sell |
16,472
-3,165
| -16% | -$86K | 0.02% | 546 |
|
|
2025
Q3 | $507K | Sell |
19,637
-1,450
| -7% | -$40.4K | 0.02% | 522 |
|
|
2025
Q2 | $582K | Buy |
21,087
+800
| +4% | +$21.1K | 0.03% | 474 |
|
|
2025
Q1 | $575K | Sell |
20,287
-36,136
| -64% | -$1.28M | 0.03% | 446 |
|
|
2024
Q4 | $2.35M | Buy |
56,423
+1,954
| +4% | +$93.4K | 0.11% | 161 |
|
|
2024
Q3 | $3.64M | Buy |
54,469
+8,390
| +18% | +$770K | 0.18% | 110 |
|
|
2024
Q2 | $5.47M | Buy |
46,079
+110
| +0.2% | +$13.9K | 0.29% | 72 |
|
|
2024
Q1 | $4.9M | Buy |
45,969
+5,919
| +15% | +$597K | 0.27% | 86 |
|
|
2023
Q4 | $3.98M | Buy |
40,050
+12,149
| +44% | +$1.02M | 0.25% | 90 |
|
|
2023
Q3 | $2.88M | Sell |
27,901
-7,007
| -20% | -$782K | 0.2% | 115 |
|
|
2023
Q2 | $4.24M | Sell |
34,908
-1,139
| -3% | -$152K | 0.28% | 84 |
|
|
2023
Q1 | $5.54M | Sell |
36,047
-271
| -0.7% | -$44.7K | 0.38% | 55 |
|
|
2022
Q4 | $6.52M | Sell |
36,318
-505
| -1% | -$82.6K | 0.45% | 42 |
|
|
2022
Q3 | $4.35M | Sell |
36,823
-314
| -0.8% | -$47.6K | 0.33% | 73 |
|
|
2022
Q2 | $5.3M | Buy |
37,137
+334
| +0.9% | +$47.7K | 0.38% | 57 |
|
|
2022
Q1 | $6.34M | Sell |
36,803
-1,220
| -3% | -$205K | 0.39% | 56 |
|
|
2021
Q4 | $9.7M | Sell |
38,023
-1,070
| -3% | -$313K | 0.59% | 33 |
|
|
2021
Q3 | $15M | Sell |
39,093
-6,731
| -15% | -$2.48M | 0.94% | 18 |
|
|
2021
Q2 | $10.8M | Sell |
45,824
-408
| -0.9% | -$72.9K | 0.76% | 19 |
|
|
2021
Q1 | $6.05M | Buy |
46,232
+546
| +1% | +$79.1K | 0.46% | 50 |
|
|
2020
Q4 | $4.77M | Buy |
45,686
+315
| +0.7% | +$31.9K | 0.4% | 59 |
|
|
2020
Q3 | $3.21M | Sell |
45,371
-3,810
| -8% | -$266K | 0.3% | 80 |
|
|
2020
Q2 | $3.15M | Sell |
49,181
-13,438
| -21% | -$736K | 0.34% | 72 |
|
|
2020
Q1 | $1.88M | Buy |
62,619
+13,000
| +26% | +$299K | 0.27% | 88 |
|
|
2019
Q4 | $980K | Buy |
49,619
+9,900
| +25% | +$176K | 0.1% | 213 |
|
|
2019
Q3 | $632K | Buy |
39,719
+8,200
| +26% | +$121K | 0.07% | 273 |
|
|
2019
Q2 | $456K | Buy |
+31,519
| New | +$677K | 0.06% | 318 |
|
Other funds holding MRNA
TP
Moors & Cabot's MRNA Position: Q3 2026 in Review
Moors & Cabot reduced its Moderna (MRNA) stake by 15% in Q3 2026, selling an estimated $237K and leaving 12,415 shares worth $2.39M. The position accounts for 0.09% of the portfolio, ranked #206.
Moors & Cabot first reported a position in MRNA in Q2 2019 and has held it in 30 quarters since. The position peaked at $15M in Q3 2021. 858 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- Moors & Cabot held 12,415 shares of Moderna worth $2.39M as of Q3 2026.
- Moors & Cabot sold 2,201 Moderna shares in Q3 2026, an estimated $237K.
- Moderna made up 0.09% of Moors & Cabot's portfolio in Q3 2026, its #206 holding.
- Moors & Cabot first reported a position in Moderna in Q2 2019 and has held it in 30 quarters since.
- Moors & Cabot's Moderna position peaked at $15M in Q3 2021.
- 858 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.